Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | CASP3 | P42574 | 1/20 | 0.69 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.69 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4570567 | 0.94 | KMT2A (0.75) | KMT2AMAPTMEN1CASP3TRPV1 | |
| SCHEMBL62862 | 0.94 | KMT2A (0.75) | KMT2AMAPTMEN1CASP3TRPV1 | |
| Hydrochloric Acid SCHEMBL28579442 | 0.92 | KMT2A (0.73) | KMT2AMAPTMEN1CASP3TRPV1 | |
| SCHEMBL1965326 | 0.90 | CA1 (0.73) | KMT2AMAPTMEN1KDM4EALDH1A1 | |
| SCHEMBL16351874 | 0.90 | CA1 (0.73) | KMT2AMAPTMEN1KDM4EALDH1A1 | |
| SCHEMBL7767342 | 0.86 | KMT2A (0.65) | KMT2AMAPTMEN1CASP3TRPV1 | |
| Benzocaine SCHEMBL8185923 | 0.86 | LMNA (0.83) | KMT2AMAPTMEN1CASP3TRPV1 | |
| Propene SCHEMBL27901997 | 0.86 | KMT2A (0.65) | KMT2AMAPTMEN1CASP3TRPV1 | |
| SCHEMBL16351851 | 0.85 | CA2 (0.66) | KMT2AMAPTMEN1KDM4EALDH1A1 | |
| SCHEMBL5556244 | 0.85 | CA12 (0.66) | KMT2AMAPTMEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960571-B2 | Silicon-based cross-coupling reagent and production method of organic compound using the same | KYOTO UNIVERSITY (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090069577-A1 | Silicon-Based Cross-Coupling Reagent and Production Method of Organic Compound Using the Same | KYOTO UNIVERSITY (JP) | 2009-03-12 | — | — | US | disclosed |
| CN-1024317-C | Antifungal agents based on amides containing phenyl group | RHONE POULENC AGROCHIMIE (FR) | 1994-04-27 | — | — | CN | disclosed |
| US-5296479-A | Treating physiological or drug-induced psychosis or dyskinesia | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-03-22 | — | — | US | disclosed |
| US-5266572-A | Antipsychotic 1-cycloalkylpiperidines | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-11-30 | — | — | US | disclosed |
| US-5243048-A | Treatment of drug-induced or physiological psychosis or dyskinesia; side effect reduction | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0490962-A4 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | — | 1993-03-03 | — | — | EP | disclosed |
| EP-0490962-A1 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-06-24 | — | — | EP | disclosed |
| US-5109002-A | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-04-28 | — | — | US | disclosed |
| WO-1991003243-A1 | ANTIPSYCHOTIC 1-CYCLOALKYLPIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069577-A1 | Silicon-Based Cross-Coupling Reagent and Production Method of Organic Compound Using the Same | DNMT1, TET3, CTCF | KMT2A 95/4885MAPT 3897/4885MEN1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.